We are live on
!
Find out more
Two Sigma Advisers Portfolio holdings
AUM
$51.4B
1-Year Est. Return
31.07%
This Fund
S&P 500
This Quarter
Est. Return
-3.02%
1 Year Est. Return
+31.07%
3 Year Est. Return
+128.94%
5 Year Est. Return
+161.75%
10 Year Est. Return
+607.04%
AUM
$34.5B
AUM Growth
-$708M
(-2%)
Cap. Flow
+$1.23B
Cap. Flow
% of AUM
3.55%
Top 10 Holdings %
Top 10 Hldgs %
13.77%
Holding
2,852
New
233
Increased
919
Reduced
1,343
Closed
332
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Enphase Energy
ENPH
|
+$342M |
| 2 |
Intel
INTC
|
+$276M |
| 3 |
TSMC
TSM
|
+$237M |
| 4 |
Procter & Gamble
PG
|
+$178M |
| 5 |
JPMorgan Chase
JPM
|
+$170M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Netflix
NFLX
|
+$383M |
| 2 |
Occidental Petroleum
OXY
|
+$321M |
| 3 |
PayPal
PYPL
|
+$316M |
| 4 |
S&P Global
SPGI
|
+$145M |
| 5 |
Datadog
DDOG
|
+$133M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 26.57% |
| 2 | Healthcare | 17.95% |
| 3 | Financials | 9.89% |
| 4 | Industrials | 9.61% |
| 5 | Consumer Discretionary | 7.56% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2376
Torrid Holdings
CURV
$271M
| $48K | ﹤0.01% |
+11,500
| New | +$60.3K |
|
2377
Aquestive Therapeutics
AQST
$472M
| $47K | ﹤0.01% |
39,900
-8,000
| -17% | -$9.04K |
|
|
VIRX
2378
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
| $47K | ﹤0.01% |
11,100
-1,900
| -15% | -$8.05K |
|
|
ML
2379
DELISTED
MoneyLion Inc.
ML
| $47K | ﹤0.01% |
1,773
| – | – |
|
|
OTIC
2380
DELISTED
Otonomy, Inc.
OTIC
| $47K | ﹤0.01% |
158,200
+38,000
| +32% | +$33.3K |
|
|
SURF
2381
DELISTED
Surface Oncology, Inc. Common Stock
SURF
| $46K | ﹤0.01% |
44,500
+11,900
| +37% | +$19K |
|
|
NVIV
2382
DELISTED
InVivo Therapeutics Holdings Corp
NVIV
| $45K | ﹤0.01% |
+10,468
| New | +$57.3K |
|
2383
Douglas Elliman
DOUG
$160M
| $44K | ﹤0.01% |
11,340
-315
| -3% | -$1.56K |
|
|
GNFT
2384
DELISTED
Genfit
GNFT
| $44K | ﹤0.01% |
12,100
-1,400
| -10% | -$5.85K |
|
2385
Five Point Holdings
FPH
$395M
| $43K | ﹤0.01% |
16,700
+3,000
| +22% | +$11K |
|
|
LX
2386
LexinFintech Holdings
LX
$239M
| $43K | ﹤0.01% |
25,700
-136,787
| -84% | -$275K |
|
2387
NetSol Technologies
NTWK
$51.3M
| $42K | ﹤0.01% |
13,400
-2,700
| -17% | -$9.08K |
|
2388
Yatra Online
YTRA
$54.7M
| $42K | ﹤0.01% |
18,700
-1,500
| -7% | -$3.87K |
|
|
WHLM
2389
DELISTED
Wilhelmina International, Inc
WHLM
| $42K | ﹤0.01% |
10,200
-900
| -8% | -$4.11K |
|
2390
Cadiz
CDZI
$259M
| $41K | ﹤0.01% |
21,600
-21,900
| -50% | -$73.7K |
|
2391
Onconetix
ONCO
$3.06M
| – | – |
0
| – | – |
|
2392
Ouster
OUST
$2.28B
| $38K | ﹤0.01% |
3,930
-21,000
| -84% | -$323K |
|
|
VINC
2393
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
| $38K | ﹤0.01% |
1,360
-115
| -8% | -$3.31K |
|
|
CRDL
2394
Cardiol Therapeutics
CRDL
$138M
| $37K | ﹤0.01% |
35,900
-26,600
| -43% | -$32.4K |
|
2395
Verrica Pharmaceuticals
VRCA
$92.8M
| $37K | ﹤0.01% |
+1,260
| New | +$43.2K |
|
|
IRD
2396
Opus Genetics
IRD
$282M
| $37K | ﹤0.01% |
18,200
-134,200
| -88% | -$290K |
|
2397
Aqua Metals
AQMS
$9.95M
| $36K | ﹤0.01% |
236
-92
| -28% | -$16.3K |
|
2398
VistaGen Therapeutics
VTGN
$9.55M
| $36K | ﹤0.01% |
+7,813
| New | +$77.4K |
|
2399
Cabaletta Bio
CABA
$445M
| $35K | ﹤0.01% |
54,400
-130,900
| -71% | -$158K |
|
2400
Flotek Industries
FTK
$856M
| $35K | ﹤0.01% |
5,888
-6,484
| -52% | -$41.6K |
|
Similar funds
CWM
VRS
FAF
BGIM
CIM
PPFA
Two Sigma Advisers's Q3 2022 Portfolio in Review
As of Q3 2022, Two Sigma Advisers held 2,852 positions worth $34.5B, down 2% from $35.3B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Two Sigma Advisers deployed $1.23B of net new capital in Q3 2022, opening 233 new positions and adding to 919 existing holdings. Its largest new stake was State Street SPDR S&P Biotech ETF: 1,329,800 shares worth $105M.
By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 24% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Netflix, an estimated $383M trimmed.
- Two Sigma Advisers's largest Q3 2022 buy was State Street SPDR S&P Biotech ETF: 1,329,800 shares worth $105M.
- Two Sigma Advisers added most to Enphase Energy in Q3 2022, an estimated $342M increase.
- Two Sigma Advisers's biggest Q3 2022 reduction was Netflix, cutting an estimated $383M.
- Two Sigma Advisers fully exited S&P Global in Q3 2022, selling an estimated $145M.
- Two Sigma Advisers's ten largest holdings make up 14% of its $34.5B portfolio in Q3 2022.
- Two Sigma Advisers opened 233 new positions and closed 332 in Q3 2022.
- Two Sigma Advisers's portfolio value fell 2% quarter-over-quarter to $34.5B.
Based on Two Sigma Advisers's 13F filing for Q3 2022, filed 14 Nov 2022.